BioMed Research International

BioMed Research International / 2019 / Article

Research Article | Open Access

Volume 2019 |Article ID 3103946 | 9 pages |

Protective Effect of Astragaloside IV on Hepatic Injury Induced by Iron Overload

Academic Editor: Elena Orlova
Received14 Mar 2019
Accepted16 Jun 2019
Published25 Jul 2019


Suitable content of iron is essential for human body, but iron overload is associated with many kinds of diseases including chronic liver damage. Recently, researchers find that iron overload promotes hepatocyte autophagy and apoptosis. However, the mechanism of iron overload in liver damage remains unclear. In this study, Lo2 cells were selected as the research object, iron dextran was a model drug, and astragaloside IV was a therapeutic drug to explore the role of iron overload. MTT assay and Annexin/PI double staining were used to measure cell viability and apoptosis. Ultrastructure was observed by transmission electron microscopy. The expression levels of apoptosis and autophagy-related proteins were determined by real-time PCR and Western Blot. The results showed that iron dextran could significantly inhibit Lo2 cell viability and increase the apoptosis rate, while astragaloside IV could reverse the inhibition of Lo2 cell viability and decrease the apoptosis rate. Transmission electron microscopy showed a significant increase in the number of autophagosomes after administration of iron dextran, and the application of astragaloside IV reduced the production of autophagosomes. LC3II/I was significantly upregulated in the model group but decreased in the astragaloside IV treatment group, and P62 showed the opposite trend. Iron dextran significantly upregulated the expression of Bax and downregulated Bcl2, while astragaloside IV reversed this trend. Finally, the inhibition of hepcidin caused by iron dextran was counteracted by astragaloside IV. In conclusion, the experimental results show that the iron overload model mainly induces excessive autophagy and apoptosis of hepatocytes, thus causing damage to hepatocytes, but astragaloside IV plays a certain therapeutic role in reversing this damage.

1. Introduction

Iron is one of the basic trace elements necessary for cellular metabolism [1]. The iron content is from 35 to 55 mg Fe/kg body weight in human [2]. The majority of iron in the body is found in hemoglobin, which is used to transport oxygen to other tissues [3]. Under normal circumstances, iron levels in the body are dynamic equilibrium. Therefore, abnormal iron level will cause a series of diseases. For example, the lack of iron can lead to diseases such as iron deficiency anemia [4] and brain dysplasia [5]. Iron overload has a certain link to chronic liver injury [6]. The phenomenon of iron overload usually occurs during some clinical treatments, such as the secondary iron overload associated with conventional transfusion therapy for thalassemia [7]. Iron overload markers also make the disease prognosis worse, with a series of toxic side effects [8].

The mechanism of cell damage and injury causing by iron overload has not been elucidated yet. However, relevant literature shows that iron overload can promote hepatocyte autophagy and apoptosis [9, 10]. Astragaloside is one of the active ingredients of traditional Chinese medicine Astragalus, which has many therapeutic effects, including anti-inflammatory [11] and antirenal fibrosis [12], and can also inhibit hair loss by inhibiting apoptotic signaling [13]. In current study, we found that iron overload could cause liver injury. Then we try to verify the mechanism by which iron overload causes excessive autophagy and apoptosis in liver cells. And we utilize astragaloside as a therapeutic drug, clarifying the mechanism in its protective effect on iron liver injury caused by iron overload from the cell autophagy and apoptosis levels.

2. Materials and Methods

2.1. Cell Line and Cell Culture

The study was conducted in accordance with the BCPT policy for experimental/preclinical studies [14]. Lo2 cells were derived from normal human hepatocytes and were given by Lu Yin’s Lab (Nanjing University of Chinese Medicine). Lo2 cells were cultured with basic DMEM containing 10% FBS (Gibco, Carlsbad, CA, USA) and 1% penicillin/streptomycin (Gibco, Carlsbad, CA, USA) in the atmosphere of 5% CO2, 37°C.

2.2. MTT Assay

Briefly, Lo2 cells were seeded in 96-well plates at a concentration of 1 × 104 cells/ml and cultured for 12 h in a cell incubator. The modeling drug iron dextran (Sigma, USA) and the therapeutic drug astragaloside IV (Aladdin, Shanghai, China) were diluted with DMEM basic medium. They were inoculated into the corresponding 96-well plates. Lo2 cells added with drug-free media were used as a negative control and cell-free wells served as blank control. The treated cells were incubated in incubator for 24 h. Then 20 μl MTT (5 mg/ml in PBS, Sigma, USA) were added to each well. After 4 h incubation, the supernatant was replaced with 150 μl of DMSO solution. Absorbance OD was measured at 490 nm and cell proliferation was calculated as follows: growth inhibition rate = (1-At/Ac) × 100%; (At, absorbance of the assay; Ac, absorbance of the control) [15].

2.3. Transmission Electron Microscopy

Lo2 cells were collected, washed once in PBS, and fixed in 2.5% glutaraldehyde (prepared in PBS) for 2 h. After fixation, cells were rinsed 3 times with 0.1 M phosphoric acid buffer and postfixed with 1% osmium tetroxide solution for 2-3 h. Then the cells were dehydrated in increasing concentrations of ethanol and embedded in Epon-812. LKB-1 ultra-microtome was used to cut the sections of epon-embedded cells into a thickness of 50-60 nm. The sections were double stained with 3% uranyl acetate followed by lead citrate and observed under transmission electron microscope (Japan JEM-1400).

2.4. Flow Cytometry (Annexin V + PI Double Staining)

Lo2 cells were seeded into a 6-well plate at the concentration of 1 × 105 cells/ml and then were cocultured with the drugs for 24 h. After that the following operations were carried out. (1) Wash the cells twice with precooled PBS, resuspend the cells in binding buffer (250 μl), and adjust the concentration to 1 × 106 cells/ml. (2) Collect 100 μl cell suspension in 5 ml flow tube and add Annexin V/Alexa Fluor 647 and propidium iodide (PI). Then mix and incubate at room temperature for 15 min (dark condition). (3) Add 400 μl of PBS to the reaction tube and analyze by flow cytometry (BD Biosciences, San Jose, CA, USA).

2.5. Immunofluorescence

The Lo2 cells were treated with drugs and cultured as previously described. Then the cells were fixed in 4% paraformaldehyde (precooled, 150 μ/well), washed with PBS, blocked with 1% BSA, incubated with primary followed with secondary antibodies, and stained with DAPI in the dark. Immunofluorescence was collected using LSM5 fluorescence microscopy (Zeiss, Germany).

2.6. Real-Time PCR

Total RNA of Lo2 cells were extracted using Trizol Reagent Kit (Invitrogen, Carlsbad, CA, USA). cDNA synthesis kit (Promega, Madison, WI, USA) was used to reverse transcribe total RNA. SYBR Green qPCR Mixes (Thermo Fisher Scientific Inc., Grand Island, NY, USA) was used to perform real-time PCR according to the user’s manual. This reaction was completed on ABI 7300 system (Applied Biosystems, Foster City, CA, USA). method was used to calculate the expression of target genes and GAPDH was used as endogenous controls. Real-time PCR primers for target genes were as below:







2.7. Western Blot

Western blot assay was performed as previously described [16]. Lo2 cells were collected and washed twice with PBS. Then the cells were lysed with RIPA lysis buffer (Solarbio, Beijing, China) containing 1% phosphatase inhibitor and centrifuged at 12000 rpm. Protein concentration was quantified using the Bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific Inc., Grand Island, NY, USA). An equal amount (30 μg) of protein was separated by 10% SDS-PAGE and then was transferred to a nitrocellulose membrane (Millipore Corp., Bedford, MA, USA). 5% skimmed milk powder was formulated with TBST solution containing 1 Tween-20 and was used to block the membrane for 2 h. The membrane was incubated with primary and secondary antibody. After that the membranes were developed by enhanced chemiluminescence (ECL) kit (Millipore, Burlington, MA, USA). Bands were recorded with Image J and normalized to GAPDH.

2.8. Statistical Analysis

All experimental results were represented as mean ± SD. t test was used for the comparison of two sets and ANOVA was used for the comparison of multiple sets. P value was limited to 0.05.

3. Results

3.1. Astragaloside IV Could Reverse the Decrease of Cell Viability Induced by Dextran Iron

Iron overload of Lo2 cells was achieved by culturing cells persistently in media containing iron dextran. First, Lo2 cells were treated with 0, 10, 20, 30, 40, 50, 60, 70, 80, and 90 μM iron dextran for 24 h. As shown in Figure 1(a), the half-inhibitory concentration of iron dextran was 63.28 μM. Then, astragaloside IV was used to treat Lo2 cells with the concentrations of 2.5, 5, 10, 20, 40, 80, and 160 μM and was found to be toxic to Lo2 cells at the concentrations of 80 μM (P <0.05) and 160 μM (P <0.01) (Figure 1(b)).

After treatment with 60 μM iron dextran, decreased cell viability was observed (Figure 1(c)). While these effects could be reversed by astragaloside IV in comparison with control, we found that cell viability was significantly restored in astragaloside IV at 10 μM (P <0.05), 20 μM (P <0.05), and 40 μM (P <0.001). Based on these results, Lo2 cells incubated with 60 μM iron dextran and/or 10, 20, and 40 μM astragaloside IV were used in following experiments. Further, we found treatment with 60 μM iron dextran significantly increased the expression level of ferritin, a maker of iron level, while astragaloside IV could attenuate these effects (Figure 1(d)).

3.2. Astragaloside IV Reduced the Apoptosis of Lo2 Cells Induced by Iron Overload

Annexin V + PI double staining kit was used to analyze early apoptotic cells, which were found to be only positive of Annexin V not PI. The proportion of early apoptotic Lo2 cells were screened by flow cytometry (FACS) under different treatments. The experimental results showed that the proportion of early apoptotic cells in the model group (giving 60μM iron dextran) was significantly higher than those in control group (p<0.001). However, the proportion of early apoptotic Lo2 cells in the treatment group (giving 10, 20, and 40μM astragaloside IV followed by 60μM iron dextran) was significantly lower compared with the model group (p<0.001) in a dose-dependent manner (Figure 2). These results suggest that astragaloside IV reduced apoptosis induced by iron overload.

3.3. Astragaloside IV Reduced the Autophagy of Lo2 Cells Induced by Iron Overload

Next transmission electron microscopy was used to observe autophagosomes under different treatment conditions in Lo2 cells. As shown in Figure 3, only a very few cells in control group were observed to have autophagosome-like structure, and the cell morphology was normal. However, a large number of autophagosomes were observed in the model group (giving 60μM iron dextran), suggesting a significant enhancement of autophagy. Excessive autophagy can cause some damage in cell structure, manifested as endoplasmic reticulum, Golgi, and other organelles harm. The astragaloside IV treatment group (given 60μM Fe, followed by 10, 20, and 40μM astragaloside IV) exhibited much fewer autophagosomes in comparison with model group, which was found to be in a dose-dependent manner. Also, cell morphology and structure tended to be normal. Moreover, we investigated autophagy induction after iron dextran and/or astragaloside IV treatment and found that iron dextran induces autophagosome formation, as measured by puncta of LC3 fusion protein in Lo2 cells compared with control group (Figure 4). Together, we supposed that astragaloside IV may play a therapeutic role in iron overload liver injury.

3.4. Astragaloside IV Attenuated Iron-Induced Apoptosis and Autophagy via Regulating Hepcidin in Lo2 Cells

Further, we wanted to explore the mechanism involved in this process. As we found that iron overload induced cell apoptosis, we detected apoptosis related makers and found that cells treated with 60μM Fe exhibited higher level of Bax and lower level of Bcl2 in comparison with control. The cells treated with 60μM Fe and astragaloside IV showed lower level of Bax and higher level of Bcl2 in comparison with the cells treated with only 60μM Fe (Figures 5(a) and 5(b)). These data suggested that Bax/Bcl-2 pathway was involved in this process.

Then the levels of p62 and LC3II / I were measured by western blot and real-time PCR. As shown in Figures 5(a) and 5(b), we found that, compared with control group, the expression of LC3II / I was increased and the expression of p62 was significantly decreased in Lo2 cells (P <0.01) in which 60μM iron dextran was applied. It was demonstrated that iron dextran induces autophagy in hepatocytes. After applying different concentrations of astragaloside IV, the expression of p62 was significantly increased (p <0.001), and LC3II/I was significantly decreased (p<0.001). It means that astragaloside IV could significantly attenuate the overautophagy phenomenon in model group.

In addition, Hepcidin is a well known regulator of iron and controls iron release from cells that recycle or store iron, thus regulating plasma iron concentrations [3]. The decrease of Hepcidin was found in the model group (60μM Fe) compared with control group, while astragaloside IV increased the expression level of Hepcidin in a dose-dependent manner compared with model group (Figure 5(c)). These results indicated that astragaloside IV attenuated iron-induced apoptosis and autophagy via upregulating hepcidin.

4. Discussion

Iron is essential for almost all organisms and is an integral part of many metabolic functions [17]. Iron has a wide range of physiological functions and is closely related to the synthesis of hemoglobin and myoglobin. It also serves as a component in essential enzyme for the body [18]. The more iron body accumulates, the more energy is released. Therefore, iron is particularly likely to accumulate in the heart, liver, kidney, and other organs with a high degree of physiological activity and biochemical functions. The level of iron tends to maintain a state of dynamic balance in the body. Abnormality of iron level will lead to a series of diseases.

Clinically, conventional blood transfusions are the best means of treating many diseases of the blood system. However, iron overload is an inevitable consequence of transfusions and is often accompanied by an increase in iron absorption from the gut [19]. Iron, on the other hand, is most likely to accumulate in energetically metabolized liver [20], so patients are prone to cause liver damage during long-term massive blood transfusions. Astragalus, as a Chinese medicine, has the effects of Buqi, diuretic swelling and promoting wound healing [21]. And astragaloside astragalus is one of the active ingredients. Therefore, it has important clinical significance and value to study the protective effect of astragaloside on liver injury and to explore its protective mechanism.

In this study, MTT test showed that giving a certain amount of iron can reduce the activity of hepatocytes. With the application of effective and nontoxic dose of astragaloside IV, liver cell vitality has been restored. This study initially confirmed that astragaloside IV could reverse the decline in viability of iron overload cells. According to the relevant literature which have reported that liver injury is caused by iron overload and induction of excessive autophagy and apoptosis in liver cells [8, 9], therefore, we observed a large number of autophagosomes in iron overload cells using transmission electron microscopy, while the number of autophagosomes was significantly reduced after treatment with astragaloside IV. Next, we used flow cytometry to detect hepatocyte apoptosis and found that the proportion of Annexin V (PI-) hepatocytes was significantly increased in iron overload cells, while the proportion was decreased after giving astragaloside IV. Finally, the expression levels of autophagy and apoptosis-related proteins were measured by immunofluorescence assay, real-time PCR, and western blot in iron overload model group and the astragaloside IV treatment group. Our results showed that LC3II / I was upregulated and p62 was downregulated in iron overload cells, while these effects could be reversed by astragaloside IV. LC3 and p62 levels are often used to measure autophagy which is a common cellular survival mechanism [22]. Degradation of p62 and reduction in LC3-I mean that autophagy occurs [23]. In this study, when Lo2 cells were exposed to iron overload, the levels of LC3-II/ LC3-I increased and those of p62 decreased. So we concluded that autophagy was activated by iron overload and astragaloside IV was found to alleviate autophagy. Moreover, we found that the expression level of Bax was increased and Bcl-2 was decreased in iron overload cells, while astragaloside IV could reverse these effects. Finally, we found that the expression of Hepcidin was inhibited by iron overload, but astragaloside IV could increase Hepcidin in a dose-dependent manner. However, the deeper mechanism of the role of astragaloside IV needs to be explored in the following study.

5. Conclusions

In summary, this study initially demonstrated the protective effect of astragaloside against iron overload model at the cellular level, which is related to the inhibition of excessive autophagy and apoptosis of iron overload hepatocytes.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Dongyu Xie, Ping Zhou, and Lin Liu contributed equally to this work.


This research is supported by the National Natural Science Foundation of China (81774252).


  1. W. Bao, Y. Fan, Y. Deng et al., “Iron overload in hereditary tyrosinemia type 1 induces liver injury through the Sp1/Tfr2/hepcidin axis,” Journal of Hepatology, vol. 65, no. 1, pp. 137–145, 2016. View at: Publisher Site | Google Scholar
  2. N. C. Andrews, “Disorders of iron metabolism,” The New England Journal of Medicine, vol. 341, no. 26, pp. 1986–1995, 1999. View at: Publisher Site | Google Scholar
  3. V. Sangkhae and E. Nemeth, “Regulation of the iron homeostatic hormone hepcidin,” Advances in Nutrition, vol. 8, no. 1, pp. 126–136, 2017. View at: Publisher Site | Google Scholar
  4. Y. Kohgo, A. Urabe, Y. Kilinç et al., “Deferasirox decreases liver iron concentration in iron-overloaded patients with myelodysplastic syndromes, aplastic anemia and other rare anemias,” Acta Haematologica, vol. 134, no. 4, pp. 233–242, 2015. View at: Publisher Site | Google Scholar
  5. A. T. Mudd, J. E. Fil, L. C. Knight, and R. N. Dilger, “Dietary iron repletion following early-life dietary iron deficiency does not correct regional volumetric or diffusion tensor changes in the developing pig brain,” Frontiers in Neurology, vol. 8, p. 735, 2017. View at: Google Scholar
  6. M. Wang, R. Liu, Y. Liang et al., “Iron overload correlates with serum liver fibrotic markers and liver dysfunction: Potential new methods to predict iron overload-related liver fibrosis in thalassemia patients,” United European Gastroenterology Journal, vol. 5, no. 1, pp. 94–103, 2016. View at: Publisher Site | Google Scholar
  7. S. Kumfu, J. Khamseekaew, S. Palee et al., “Combined iron chelator and T-type calcium channel blocker exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice,” European Journal of Pharmacology, vol. 822, pp. 43–50, 2018. View at: Publisher Site | Google Scholar
  8. N. Shenoy, N. Vallumsetla, E. Rachmilewitz, A. Verma, and Y. Ginzburg, “Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome,” Blood, vol. 124, no. 6, pp. 873–881, 2014. View at: Publisher Site | Google Scholar
  9. W. R. Dong MW, B. Wu, and C. B. Liu, “Protective effects of lycopene on cell autophagy in iron overload rats,” Journal of Wenzhou Medical College, vol. 42, no. 3, pp. 214–217, 2012. View at: Google Scholar
  10. X. H. Ye ZH, Z. Z. Qian, J. Ye et al., “Protective effect of astragaloside on liver injury induced by iron overload in mice,” Chinese Journal of Experimental Traditional Medical Formulaevol, vol. 24, no. 7, pp. 1–6, 2018. View at: Google Scholar
  11. Y. Zhao, Q. Li, W. Zhao et al., “Astragaloside IV and cycloastragenol are equally effective in inhibition of endoplasmic reticulum stress-associated TXNIP/NLRP3 inflammasome activation in the endothelium,” Journal of Ethnopharmacology, vol. 169, pp. 210–218, 2015. View at: Publisher Site | Google Scholar
  12. Y. Wang, C. Lin, Q. Ren, Y. Liu, and X. Yang, “Astragaloside effect on TGF-beta1, SMAD2/3, and alpha-SMA expression in the kidney tissues of diabetic KKAy mice,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 6, pp. 6828–6834, 2015. View at: Google Scholar
  13. M. H. Kim, S. Kim, W. M. Yang, and S. V. Pizzo, “Beneficial effects of astragaloside IV for hair loss via inhibition of Fas/Fas L-mediated apoptotic signaling,” PLoS ONE, vol. 9, no. 3, p. e92984, 2014. View at: Publisher Site | Google Scholar
  14. P. Tveden-Nyborg, T. K. Bergmann, and J. Lykkesfeldt, “Basic & clinical pharmacology & toxicology policy for experimental and clinical studies,” Basic & Clinical Pharmacology & Toxicology, vol. 123, no. 3, pp. 233–235, 2018. View at: Google Scholar
  15. S. Chen, Y. Fang, L. Ma, S. Liu, and X. Li, “Realgar-induced apoptosis and differentiation in all-trans retinoic acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cells,” International Journal of Oncology, vol. 40, no. 4, pp. 1089–1096, 2012. View at: Publisher Site | Google Scholar
  16. Z. Zhang, L. Cheng, J. Li et al., “Inhibition of the Wnt/b-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer,” Cancer Research, vol. 78, no. 12, pp. 3147–3162, 2018. View at: Google Scholar
  17. D. Z. Naigamwalla, J. A. Webb, and U. Giger, “Iron deficiency anemia,” Canadian Veterinary Journal, vol. 53, no. 3, pp. 250–256, 2012. View at: Google Scholar
  18. D. Yun, M. Dey, L. J. Higgins, F. Yan, H. Liu, and C. L. Drennan, “Structural basis of regiospecificity of a mononuclear iron enzyme in antibiotic fosfomycin biosynthesis,” Journal of the American Chemical Society, vol. 133, no. 29, pp. 11262–11269, 2011. View at: Publisher Site | Google Scholar
  19. M. Marsella and C. Borgna-Pignatti, “Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease,” Hematology/Oncology Clinics of North America, vol. 28, no. 4, pp. 703–727, 2014. View at: Publisher Site | Google Scholar
  20. S. Galimberti, P. Trombini, D. P. Bernasconi et al., “Simultaneous liver iron and fat measures by magnetic resonance imaging in patients with hyperferritinemia,” Scandinavian Journal of Gastroenterology, vol. 50, no. 4, pp. 429–438, 2015. View at: Publisher Site | Google Scholar
  21. W. Y. Shan JJ, Y. Q. Weng, CY. Xie, D. Liu, and Z. B. Hu, “Comparing compositions and immunoactivities of polysaccharide in hair root of Astragalus membranaceus and cultivated A.membranaceus,” Chinese Traditional and Herbal Drugs, vol. 33, no. 12, pp. 1096–1099, 2002. View at: Google Scholar
  22. P. Jiang and N. Mizushima, “LC3- and p62-based biochemical methods for the analysis of autophagy progression in mammalian cells,” Methods, vol. 75, pp. 13–18, 2015. View at: Publisher Site | Google Scholar
  23. Z. Liang, G. Lin, B. Yu et al., “The role of autophagy in the radiosensitivity of the radioresistant human nasopharyngeal carcinoma cell line CNE-2R,” Cancer Management and Research, vol. 10, pp. 4125–4134, 2018. View at: Publisher Site | Google Scholar

Copyright © 2019 Dongyu Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

479 Views | 233 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.